CD4 and Its Relevance to Advanced Glycation End Products in Tuberculosis Patients with Co-morbidity Diabetes
DOI:
https://doi.org/10.3889/oamjms.2018.347Keywords:
Diabetes, TBs, CD4, AGEsAbstract
BACKGROUND: Tuberculosis (TB) is one of the most common infectious diseases found in developing countries. One of the risk factors for TB is diabetes, a chronic metabolic disorder characterised by hyperglycemia. The altered in glucose metabolism will cause dysfunction of phagocyte and antibacterial that furthermore impaired activation of natural killer cells, dendritic cells. These together will alter the balance of T-cell immunity. Under hyperglycemic conditions, AGEs (advanced glycation end products) was increasingly formed and was believed to play a role in cell dysfunctions and diabetic complications. The CD4 deficiency will alter the immunity status in diabetes and TB with co-morbidity diabetes.
AIM: This aim of this study was to evaluate CD4, and it’s relevant to Advanced Glycation End Products (AGEs) in TB with co-morbidity diabetes.
METHODS: This is a case-control study with a total of 80 patients (40 diabetes and 40 TB with co-morbidity diabetes were recruited from Murni Teguh memorial Hospital Medan after ethical approval from Health Research Ethical Committee. The CD4, AGEs, Blood glucose and HbA1C were measured.
RESULTS: There was no statistical difference of CD4, HbA1C and blood glucose within diabetes and TB with co-morbidity diabetes but BMI (p = 0.009) and AGEs (p = 0.001) did. The CD4 below 500 were seen in 15% diabetes and 25% in TB with co-morbidity diabetes but did not show statistical significance difference (p = 0.07). No correlation was found between CD4 and AGEs in TB with co-morbidity diabetes (p = 0.44).
CONCLUSION: The CD4 was not correlated significantly with AGEs.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Atkins RC, Zimmet P. Diabetic kidney disease: Act now or pay later. Saudi J Kidney Dus Transpl 2012; 21:217-21.
Mark A, Joshua A, Thomas FL, Francesco C. Diabetes and vascular disease: pathophysiology clinical consequences, and medical therapy: part I. Circulation. 2003. PMid:14517147
Alberti KG, Zimmet PF. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998; 15(7):539-53. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Dobler CC, Flack JR, Marks GB. Risk of Tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open. 2012; 2:e000666. https://doi.org/10.1136/bmjopen-2011-000666 PMid:22331390 PMCid:PMC3282295
Young F, Wotton CJ, Critchley JA et al. Increased risk of Tuberculosis disease in people with diabetes mellitus: record-linkage study in a UK population. J Epidemiol Community Health. 2012; 66:519–23. https://doi.org/10.1136/jech.2010.114595 PMid:21109542
Leung CC, Lam TH, Chan WM et al. Diabetic control and risk of Tuberculosis: a cohort study. Am J Epidemiol. 2008; 167:1486–94. https://doi.org/10.1093/aje/kwn075 PMid:18400769
Perez A, Brown HS III, Restrepo BI. Association between Tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg. 2006; 74:604–11. https://doi.org/10.4269/ajtmh.2006.74.604 PMid:16606993 PMCid:PMC1464139
WHO. Global TBs Report 2013. Geneva: World Health Organisation, 2013. URL http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
Restrepo BI, Camerlin AJ, Rahbar MH et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed Tuberculosis cases. Bull World Health Organ. 2011; 89:352–9. https://doi.org/10.2471/BLT.10.085738 PMid:21556303 PMCid:PMC3089389
Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: Pathogenesis, management, and relationship to glycaemic control. Diabetes Metab Res Rev. 2007; 23:3–13. https://doi.org/10.1002/dmrr.682 PMid:16960917
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: Convergence of two epidemics. Lancet Infect Dis. 2009; 9:737–46. https://doi.org/10.1016/S1473-3099(09)70282-8
Ruslami R, Aarniutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for Tuberculosis control and patient care. Trop Med Int Health. 2010; 15:1289–99. https://doi.org/10.1111/j.1365-3156.2010.02625.x PMid:20955495
Baker MA, Harries AD, Jeon CY et al. The impact of diabetes on Tuberculosis treatment outcomes: a systematic review. BMC Med. 2011; 9:81. https://doi.org/10.1186/1741-7015-9-81 PMid:21722362 PMCid:PMC3155828
Magee MJ, Foote M, Maggio DM et al. Diabetes mellitus and risk of all-cause mortality among patients with Tuberculosis in the state of Georgia, 2009–2012. Ann Epidemiol. 2014; 24:369–75. https://doi.org/10.1016/j.annepidem.2014.01.012 PMid:24613196 PMCid:PMC4011933
Kelly H, Jodie M, Tahnee Br, Brenda G, Rush C and Natkunam K. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 2014; 144:171-185.
Kerstin Nowotny, Tobias Jung, Annika Höhn, Daniela Weber and Tilman Grune. Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. Biomolecules. 2015; 5:194-222. https://doi.org/10.3390/biom5010194 PMid:25786107 PMCid:PMC4384119
Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M. Multifunctional T H 1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature medicine. 2007; 13(7):843. https://doi.org/10.1038/nm1592 PMid:17558415
Ciuffreda, D. et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol. 2008; 38:2665–77. https://doi.org/10.1002/eji.200838336 PMid:18958874
Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J, Amara RR. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. Journal of virology. 2007; 81(21):12071-6. https://doi.org/10.1128/JVI.01261-07 PMid:17728221 PMCid:PMC2168799
Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R, Hanekom WA, Lange C, Wilkinson RJ. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. American journal of respiratory and critical care medicine. 2009; 180(12):1262-70. https://doi.org/10.1164/rccm.200907-1011OC PMid:19797156 PMCid:PMC2796736
Day CL, Abrahams DA, Lerumo L, van Rensburg EJ, Stone L, O'rie T, Pienaar B, de Kock M, Kaplan G, Mahomed H, Dheda K. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. The Journal of Immunology. 2011:1101122. https://doi.org/10.4049/jimmunol.1101122
Hull MW, Phillips P, Montaner JS. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest. 2008; 134(6):1287-98. https://doi.org/10.1378/chest.08-0364 PMid:19059959
Helen V, Uribarri. Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both? Curr Diab Rep. 2014; 14(1):453. https://doi.org/10.1007/s11892-013-0453-1 PMid:24292971 PMCid:PMC3903318
Ann SB. The Epidemic of Obesity and Diabetes Trends and Treatments. Tex Heart Inst J. 2011; 38(2):142–144.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Sry Suryani Widjaja, - Rusdiana, Maya Savira
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
